Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scene And Heard At BIO - From The IN VIVO Blog

This article was originally published in The Pink Sheet Daily

Executive Summary

Take our molecules...please! And "Pim's" cup runneth over, from BIO's annual meeting in Chicago.

You may also be interested in...



Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma

Citing different financial needs, Versartis' backers have created Diartis to take its GLP-1 molecule to proof of concept, while Versartis focuses on human growth hormone.

Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma

Citing different financial needs, Versartis' backers have created Diartis to take its GLP-1 molecule to proof of concept, while Versartis focuses on human growth hormone.

Innate Therapeutics Wins $550K From Fast Forward For Therapy Aimed At Progressive MS

Validation from the venture philanthropy garnered the New Zealand biotech another NZD600,000 from the NZ government.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel